Patients in the HER2-overexpressing and triple negative groups were more likely to have a higher grade of tumor, with 32% of these two groups being grade 3 at the time of diagnosis compared with 14% of the luminal cohort (P=0.000; Table I). The gene discussed is ERBB2; the disease is neoplasm.